National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 58262 [2018-25191]
Download as PDF
<![CDATA[
khammond on DSK30JT082PROD with NOTICES
58262
Federal Register / Vol. 83, No. 223 / Monday, November 19, 2018 / Notices
Services is hereby giving notice that the
National Biodefense Science Board
(NBSB) will hold a public
teleconference on December 13, 2018.
DATES: The NBSB Public Teleconference
is December 13, 2018, from 2:00 p.m. to
4:00 p.m. Eastern Standard Time (EST).
ADDRESSES: We encourage members of
the public to attend the public meetings.
To register, send an email to nbsb@
hhs.gov with ‘‘NBSB Registration’’ in
the subject line. Submit your comments
to nbsb@hhs.gov, the NBSB Contact
Form located at https://www.phe.gov/
Preparedness/legal/boards/nbsb/Pages/
RFNBSBComments.aspx. For additional
information, visit the NBSB website
located at https://www.phe.gov/nbsb.
SUPPLEMENTARY INFORMATION: The NBSB
is authorized under Section 319M of the
Public PHS Act (42 U.S.C. 247d–7f), as
added by Section 402 of the Pandemic
and All-Hazards Preparedness Act of
2006 and amended by Section 404 of the
Pandemic and All-Hazards
Preparedness Reauthorization Act. The
Board is governed by the Federal
Advisory Committee Act (5 U.S.C.
App.), which sets forth standards for the
formation and use of advisory
committees. The NBSB provides expert
advice and guidance on scientific,
technical, and other matters of special
interest to the Department regarding
current and future chemical, biological,
nuclear, and radiological agents,
whether naturally occurring, accidental,
or deliberate.
Background: The December 13, 2018,
NBSB public teleconference is
dedicated to the discussion of
recommendations on two topics: (1)
Strategic improvements to the National
Disaster Medical System (NDMS) and
(2) implementation of the National
Biodefense Strategy. We will post
modifications to the agenda on the
NBSB meeting website, which is located
at https://www.phe.gov/nbsb.
Availability of Materials: We will post
all teleconference materials prior to the
teleconference on December 13, 2018, at
the website located at https://
www.phe.gov/nbsb.
Procedures for Providing Public Input:
Members of the public may attend the
public teleconference via a toll-free callin phone number, which is available on
the NBSB website at https://
www.phe.gov/nbsb.
We encourage members of the public
to provide written comments that are
relevant to the NBSB public
teleconference prior to December 13,
2018. Send written comments by email
to nbsb@hhs.gov with ‘‘NBSB Public
Comment’’ in the subject line. The
VerDate Sep<11>2014
17:20 Nov 16, 2018
Jkt 247001
NBSB Chair will respond to comments
received by December 12, 2018, during
the public teleconference.
Dated: November 8, 2018.
Robert P. Kadlec,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2018–25131 Filed 11–16–18; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID 2018 Omnibus BAA
(HHS–NIH–NIAID–BAA2018) Research Area
001: Development of Therapeutic Products
for Biodefense, Anti-Microbial Resistant
(AMR) Infections and Emerging Infectious
Diseases.
Date: December 11–12, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Kumud K. Singh, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, MSC–9823, Rockville, MD
20852, 301–761–7830, kumud.singh@
nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID Investigator Initiated
Program Project Applications (P01).
Date: December 11, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Priti Mehrotra, Ph.D.,
Chief, Immunology Review Branch, Scientific
Frm 00041
Fmt 4703
Sfmt 4703
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25191 Filed 11–16–18; 8:45 am]
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
PO 00000
Review Program, Division of Extramural
Activities, Room #3G40, National Institutes
of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892–7616, 240–669–
5066, pmehrotra@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Chimeric Antigen
Receptor (CAR) Therapies for the
Treatment of FMS-Like Tyrosine
Kinase 3 (FLT3) Expressing Cancers
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this Notice to ElevateBio.
(‘‘Elevate’’), located in Cambridge, MA.
SUMMARY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before December 4, 2018 will be
considered.
DATES:
Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Jim Knabb, Senior
Technology Transfer Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530, MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702; Telephone: (240)-276–7856;
Facsimile: (240)-276–5504; Email:
jim.knabb@nih.gov.
ADDRESSES:
SUPPLEMENTARY INFORMATION:
E:\FR\FM\19NON1.SGM
19NON1
]]>Agencies
[Federal Register Volume 83, Number 223 (Monday, November 19, 2018)]
[Notices]
[Page 58262]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25191]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID 2018 Omnibus BAA (HHS-NIH-
NIAID-BAA2018) Research Area 001: Development of Therapeutic
Products for Biodefense, Anti-Microbial Resistant (AMR) Infections
and Emerging Infectious Diseases.
Date: December 11-12, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Kumud K. Singh, Ph.D., Scientific Review
Officer, Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers
Lane, MSC-9823, Rockville, MD 20852, 301-761-7830,
[email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel NIAID Investigator Initiated Program
Project Applications (P01).
Date: December 11, 2018.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Priti Mehrotra, Ph.D., Chief, Immunology Review
Branch, Scientific Review Program, Division of Extramural
Activities, Room #3G40, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC 9823, Bethesda, MD 20892-7616, 240-669-5066,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25191 Filed 11-16-18; 8:45 am]
BILLING CODE 4140-01-P
